Clinical Chemistry Global Market Report 2024

Clinical chemistry is a quantitative discipline focused on measuring the concentrations of biologically significant chemicals, or analytes, in bodily fluids.

The primary product categories in clinical chemistry comprise analyzers, reagents, and consumables. The term 'analyzer' refers to a laboratory device used to determine the concentration of specific compounds in samples of serum, plasma, urine, and other bodily fluids. These analyzers initiate reactions using reagents, typically applied to the pale-yellow supernatant part (serum) obtained from centrifuged blood or urine samples. Various applications of clinical chemistry include general chemistry tests, liver function tests, kidney function tests, urinalysis, electrolyte panels, lipid profiles, specialty chemical tests, and others. These products find application in hospitals, diagnostic and pathology centers, ambulatory surgery centers, and various other end-user settings.

The clinical chemistry market research report is one of a series of new reports that provides clinical chemistry market statistics, including clinical chemistry industry global market size, regional shares, competitors with clinical chemistry market share, detailed clinical chemistry market segments, market trends and opportunities, and any further data you may need to thrive in the clinical chemistry industry. This anomaly detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The clinical chemistry market size has grown strongly in recent years. It will grow from $14.04 billion in 2023 to $15.02 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historical period can be attributed to several factors, including an increased demand for diagnostic testing, growth in the healthcare industry, an aging population, heightened focus on disease diagnosis and management, and increased investments in research and development.

The clinical chemistry market size is expected to see strong growth in the next few years. It will grow to $20.06 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The anticipated growth in the forecast period can be attributed to various factors, including the increasing demand for precision medicine, a growing need for biomarker discovery, rising demand for personalized healthcare, the emergence of infectious diseases, and the expanding role of telemedicine and remote monitoring. Noteworthy trends expected in the forecast period encompass the integration of advanced analytical techniques, incorporation of AI and machine learning, ongoing technological innovations, the adoption of laboratory automation, and the introduction of cutting-edge solutions.

The anticipated increase in the prevalence of chronic diseases is expected to drive the growth of the clinical chemistry market. Chronic diseases, characterized by prolonged duration and the need for continuous medical care, significantly impact global health, with conditions such as diabetes, cancer, and heart disease being leading causes of death and disability. Clinical chemistry plays a vital role in developing and improving techniques for assessing the status and risk of various chronic diseases, including cardiovascular disease, diabetes, and hormone disorders. Additionally, it supports laboratory initiatives related to infectious diseases and flu. According to a September 2023 report from the World Health Organization (WHO), chronic diseases account for 74% of global deaths, totaling 41 million people annually. Hence, the increasing prevalence of chronic diseases is a key driver for the growth of the clinical chemistry market.

The growth of the clinical chemistry market is further fueled by the rising geriatric population. This demographic, consisting of individuals aged 65 or older, plays a crucial role in the demand for clinical chemistry, as it is instrumental in managing age-related diseases such as diabetes, cardiovascular issues, and osteoporosis. According to an October 2022 report from the World Health Organization, the global elderly population is projected to reach 2.1 billion by 2050, with 1 in 6 individuals expected to be 60 or older by 2030. The increasing geriatric population is thus a significant factor contributing to the growth of the clinical chemistry market.

Moreover, technological advancements are a notable trend gaining traction in the clinical chemistry market. Key players in the sector are actively adopting new technological solutions to enhance their market position. For instance, in July 2021, the Core Clinical Chemistry Lab, affiliated with Vanderbilt University in the U.S., introduced a faster and higher-volume automated chemistry line. This advancement doubled the daily capacity for routine critical tests, analyzing electrolyte, protein, and enzyme levels in patient blood samples. This signifies a broader trend in the industry where technological innovations are being leveraged to improve efficiency and expand testing capabilities, contributing to the overall growth of the clinical chemistry market.

Major companies operating in the clinical chemistry market are intensifying their focus on introducing advanced diagnostic systems, such as the Atellica CI Analyzer, to gain a competitive edge in the market. The Atellica CI Analyzer is a compact testing system developed by Siemens Healthineers, a Germany-based healthcare company. Launched in July 2023, this analyzer is designed to address challenges faced by laboratories in delivering high-quality diagnostics and improving community health. Equipped with features like microvolume technology, an IMT sensor, and independent integration, the Atellica CI Analyzer maximizes test yield, ensures quality results, and maintains high throughput. Offering a comprehensive range of over 200 assays across 20 disease states, it aids in standardizing results and streamlining workflows for entire lab networks.

In a separate development, in May 2021, Roche, a Switzerland-based pharmaceutical and diagnostics company, acquired GenMark Diagnostics for USD 1.8 billion. This strategic acquisition allows Roche to expand its line of molecular diagnostic products and incorporate techniques that provide quick and critical information for patients and healthcare professionals. The addition of GenMark's ePlex technologies enhances Roche's capabilities in managing infectious diseases and antibiotic resistance. GenMark Diagnostics, based in the United States, specializes in providing multiplex molecular diagnostic solutions with expertise in syndromic testing and clinical chemistry.

Major companies operating in the clinical chemistry market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., ELITechGroup SAS, Beckman Coulter Inc., Thermo Fisher Scientific Inc., Siemens AG, Ortho Clinical Diagnostics Holdings PLC, Diatron Mi Apac Private Limited, Nova Biomedical Corporation, Johnson & Johnson Services Inc., Alfa Wassermann USA Inc., HORIBA Ltd., Mindray Medical International Limited, Randox Laboratories Limited, SYNLAB International GmbH, Agilent Technologies Inc., Alcami Corporation, ARUP Laboratories Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Charles River Laboratories International Inc., Danaher Corporation, Eurofins Scientific SE, GE Healthcare Technologies Ltd., Horiba Medical Inc., Laboratory Corporation, Luminex Corporation, Medtronic PLC, PerkinElmer Inc., Quest Diagnostics Incorporated, Sysmex Corporation, Tosoh Corporation, Trinity Biotech PLC, Waters Corporation, Werfen S.A.

North America was the largest region in the chemical chemistry market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical chemistry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the clinical chemistry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The clinical chemistry market includes revenues earned by assays and analyzers. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.